The Drug Controller General of India (DCGI) has given the nod for conducting phase 3 trials to test Biological E’s Covid vaccine Corbevax as booster shots, News18.com has learnt. The Hyderabad-based firm on Tuesday received permission as emergency-use authorisation for manufacturing and marketing the first indigenously developed receptor-binding domain (RBD) protein subunit vaccine against SARS-CoV-2.

RBD protein subunit vaccines are useful for people with compromised immune systems, have no live components because of which there is no risk of the vaccine prompting disease, and are also considered largely stable.

Source: News18